Table 2.
Risk for Non-Hodgkin Lymphoma by tertiles (T1–T3) of circulating markersa
| Analyte | T1 | T2 | T3 | ptrend b |
|---|---|---|---|---|
| Adiponectin, μg/mL | <5.6 | 5.6–<11.0 | ≥11.0 | |
| Cases/controls | 98/177 | 84/184 | 90/180 | |
| OR (95% CI) all | 1.00 | 0.81 (0.55, 1.17) | 0.87 (0.58, 1.30) | 0.67 |
| OR (95% CI) >1 y onlyc | 1.00 | 0.78 (0.50, 1.19) | 0.87 (0.55, 1.36) | 0.63 |
| Leptin, ng/ml | <6.4 | 6.4–<14.9 | ≥14.9 | |
| Cases/controls | 105/166 | 91/182 | 76/192 | |
| OR (95% CI) all | 1.00 | 0.72 (0.49, 1.05) | 0.48 (0.30, 0.76) | <0.001 |
| OR (95% CI) >1 y onlyc | 1.00 | 0.73 (0.48, 1.13) | 0.61 (0.37, 1.02) | 0.05 |
| IFN-γ, pg/mL | <0.5 | 0.5–<0.9 | ≥0.9 | |
| Cases/controls | 93/172 | 80/195 | 99/174 | |
| OR (95% CI) all | 1.00 | 0.75 (0.51, 1.10) | 1.05 (0.72, 1.55) | 0.61 |
| OR (95% CI) >1 y onlyc | 1.00 | 0.69 (0.44, 1.06) | 1.02 (0.66, 1.57) | 0.82 |
| IL-1β, pg/mL | <0.6 | 0.6–<1.6 | ≥1.6 | |
| Cases/controls | 93/176 | 83/189 | 96/176 | |
| OR (95% CI) all | 1.00 | 0.81 (0.54, 1.22) | 1.04 (0.69, 1.56) | 0.09 |
| OR (95% CI) >1 y onlyc | 1.00 | 1.00 (0.64, 1.56) | 1.00 (0.63, 1.60) | 0.52 |
| IL-2, pg/mL | <0.9 | 0.9–<1.9 | ≥1.9 | |
| Cases/controls | 86/182 | 91/183 | 95/176 | |
| OR (95% CI) all | 1.00 | 1.07 (0.72, 1.58) | 1.16 (0.79, 1.72) | 0.14 |
| OR (95% CI) >1 y onlyc | 1.00 | 1.08 (0.69, 1.69) | 1.10 (0.70, 1.73) | 0.51 |
| IL-4, pg/mL | <1.4 | 1.4–<3.4 | ≥3.4 | |
| Cases/controls | 87/182 | 97/177 | 88/182 | |
| OR (95% CI) all | 1.00 | 1.14 (0.79, 1.65) | 1.00 (0.65, 1.55) | 0.25 |
| OR (95% CI) >1 y onlyc | 1.00 | 1.26 (0.83, 1.92) | 1.01 (0.62, 1.65) | 0.53 |
| IL-5, pg/mL | <0.4 | 0.4–<0.9 | ≥0.9 | |
| Cases/controls | 87/181 | 87/185 | 98/175 | |
| OR (95% CI) all | 1.00 | 0.96 (0.60, 1.55) | 1.20 (0.71, 2.02) | 0.14 |
| OR (95% CI) >1 y onlyc | 1.00 | 1.05 (0.70, 1.58) | 1.32 (0.84, 2.07) | 0.47 |
| IL-6, pg/mL | <1.1 | 1.1–<2.7 | ≥2.7 | |
| Cases/controls | 85/187 | 86/189 | 101/165 | |
| OR (95% CI) all | 1.00 | 1.02 (0.71, 1.48) | 1.39 (0.95, 2.02) | 0.17 |
| OR (95% CI) >1 y onlyc | 1.00 | 0.93 (0.62, 1.41) | 1.11 (0.72, 1.70) | 0.97 |
| IL-8, pg/mL | <6.7 | 6.7–<14.6 | ≥14.6 | |
| Cases/controls | 79/188 | 94/179 | 99/174 | |
| OR (95% CI) all | 1.00 | 1.30 (0.88, 1.91) | 1.45 (0.97, 2.16) | 0.08 |
| OR (95% CI) >1 y onlyc | 1.00 | 1.08 (0.70, 1.65) | 1.21 (0.77, 1.90) | 0.26 |
| IL-10, pg/mL | <0.6 | 0.6–<1.6 | ≥1.6 | |
| Cases/controls | 68/197 | 77/194 | 127/150 | |
| OR (95% CI) all | 1.00 | 1.28 (0.85, 1.94) | 3.07 (2.02, 4.66) | <0.001 |
| OR (95% CI) >1 y onlyc | 1.00 | 1.07 (0.67, 1.69) | 2.20 (1.38, 3.51) | 0.06 |
| TNF-α, pg/mL | <1.7 | 1.7–<4.6 | ≥4.6 | |
| Cases/controls | 95/177 | 81/191 | 96/173 | |
| OR (95% CI) all | 1.00 | 0.78 (0.54, 1.14) | 1.04 (0.70, 1.54) | 0.05 |
| OR (95% CI) >1 y onlyc | 1.00 | 0.73 (0.48, 1.11) | 0.98 (0.63, 1.54) | 0.23 |
| CRP, mg/L | <1.0 | 1.1–<3.1 | ≥3.1 | |
| Cases/controls | 92/183 | 85/178 | 94/178 | |
| OR (95% CI) all | 1.00 | 0.94 (0.66, 1.36) | 1.05 (0.72, 1.52) | 0.32 |
| OR (95% CI) >1 y onlyc | 1.00 | 0.78 (0.51, 1.18) | 0.85 (0.56, 1.31) | 0.70 |
| Summary measurec | <−0.5 | −0.5–<0.1 | ≥0.1 | |
| Cases/controls | 94/177 | 81/191 | 97/173 | |
| OR (95% CI) all | 1.00 | 0.79 (0.53, 1.16) | 1.08 (0.73, 1.60) | 0.08 |
| OR (95% CI) >1 y onlyc | 1.00 | 0.86 (0.55, 1.36) | 1.02 (0.65, 1.60) | 0.42 |
Abbreviations: BMI, body mass index; CRP, C-reactive protein IFN, Interferon; IL, Interleukin; TNF, Tumor neurosis factor
OR and 95% CI estimated by conditional logistic regression; cases and controls matched on sex, birthdate (± 1 year), ethnicity (white, Japanese American, Latino, African American, or Native Hawaiian), location (California or Hawaii), date of blood draw (within ±1 year), time of day of blood draw, and fasting hours prior to blood draw (0–<6, 6–<8, 8–<10, or ≥10). Missing data for leptin (1) and CRP (3).
p for trend based on the Wald χ2 test of a log-transformed continuous variable.
N=642 (219 cases and 423 controls)
Composite score from principal components analysis of log-transformed IL-1β, IL-4, IL-5, IL-6, IL-8, and TNF-α.